trending Market Intelligence /marketintelligence/en/news-insights/trending/gZ58bkvgpBxH_QpLLU5_zA2 content esgSubNav
In This List

US FDA grants Lupin tentative approval to market generic ulcer drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


US FDA grants Lupin tentative approval to market generic ulcer drug

The U.S. FDA granted Lupin Ltd. tentative approval to market its balasalazide disodium tablets, a generic version of Salix Pharmaceutical Inc.'s Giazo.

The drug is meant for the treatment of ulcerative colitis in male patients above the age of 18 years.